Cargando…

Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation

SIMPLE SUMMARY: The anti-tumor role of Fasudil in EGFR-mutation NSCLC as well as its mechanism are largely unknown. Here, we show that Fasudil could effectively inhibit EGFR-mutation cell growth and enhance the sensitivity of gefitinib-resistant NSCLC cells to gefitinib by suppressing intracellular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Tingting, Deng, Jingjing, Chen, Wenjuan, Xu, Juanjuan, Yang, Guanghai, Zhou, Mei, Lv, Zhilei, Wang, Sufei, Song, Siwei, Tan, Xueyun, Yin, Zhengrong, Li, Yumei, Jin, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563767/ https://www.ncbi.nlm.nih.gov/pubmed/36230634 http://dx.doi.org/10.3390/cancers14194709

Ejemplares similares

Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells
por: Zhu, Yinsong, et al.
Publicado: (2015)

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
por: Tan, Xueyun, et al.
Publicado: (2022)

The Correlation Between Clinical Features and Viral RNA Shedding in Outpatients With COVID-19
por: Liao, Tingting, et al.
Publicado: (2020)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

Changes in glomerular filtration rate and metabolomic differences in severely ill coronavirus disease survivors 3 months after discharge
por: Zhou, Mei, et al.
Publicado: (2022)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Comprehensive genomic and prognostic analysis of the IL-17 family genes in lung cancer
por: Liao, Tingting, et al.
Publicado: (2019)

Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
por: Qin, Yijia, et al.
Publicado: (2016)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line
por: Yan, Dong, et al.
Publicado: (2015)

Comparison of clinical characteristics among younger and elderly deceased patients with COVID-19: a retrospective study
por: Tan, Xueyun, et al.
Publicado: (2020)

POU6F1 cooperates with RORA to suppress the proliferation of lung adenocarcinoma by downregulating HIF1A signaling pathway
por: Xiao, Wenjing, et al.
Publicado: (2022)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Therapeutic potentials of fasudil in liver fibrosis
por: Xi, Yue, et al.
Publicado: (2021)

Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells
por: Xiao, Juanjuan, et al.
Publicado: (2019)

Combination of fasudil and celecoxib promotes the recovery of injured spinal cord in rats better than celecoxib or fasudil alone
por: Hou, Xiao-lin, et al.
Publicado: (2015)

Inhibition of GPR30 sensitized gefitinib to NSCLC cells via regulation of epithelial-mesenchymal transition
por: Yang, Xiaomin, et al.
Publicado: (2023)

Effects of fasudil on blood–brain barrier integrity
por: Sato, Kei, et al.
Publicado: (2022)

Pre-treatment With Fasudil Prevents Neomycin-Induced Hair Cell Damage by Reducing the Accumulation of Reactive Oxygen Species
por: Zhang, Yanqiu, et al.
Publicado: (2019)

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
por: Tiseo, M, et al.
Publicado: (2010)

The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations
por: Song, Ruiqiang, et al.
Publicado: (2022)

Construction and validation of a nomogram based on N6‐Methylandenosine‐related lncRNAs for predicting the prognosis of non‐small cell lung cancer patients
por: Xiao, Wenjing, et al.
Publicado: (2022)

FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy
por: Guan, Shaoxing, et al.
Publicado: (2022)

Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy
por: Zhou, E, et al.
Publicado: (2021)

The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
por: Xin, Shuang, et al.
Publicado: (2015)

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines
por: Galetti, Maricla, et al.
Publicado: (2015)

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort Study
por: Dai, Lili, et al.
Publicado: (2022)

Biphasic function of GSK3β in gefitinib‑resistant NSCLC with or without EGFR mutations
por: Li, Junzhe, et al.
Publicado: (2023)

Evaluation on efficacy and safety of the addition of X-knife therapy to gefitinib in NSCLC patients with symptomatic brain metastases
por: Cai, Linbo, et al.
Publicado: (2016)

Effects of rosuvastatin combined with fasudil therapy on rabbits with dyslipidemia
por: Li, Zhiming, et al.
Publicado: (2015)

Metabolomics study of fasudil on cisplatin-induced kidney injury
por: Xia, Demeng, et al.
Publicado: (2019)

Effect of Fasudil on remyelination following cuprizone‐induced demyelination
por: Wang, Jing, et al.
Publicado: (2019)

Hydrochloride fasudil attenuates brain injury in ICH rats
por: Li, Limin, et al.
Publicado: (2020)

The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression: DUXAP10 contributes to gefitinib resistance by repressing OAS2
por: Ren, Shengnan, et al.
Publicado: (2022)

Clinical Characteristics and Outcomes of Severe or Critical COVID-19 Patients Presenting No Respiratory Symptoms or Fever at Onset
por: Xu, Juanjuan, et al.
Publicado: (2021)

AURKA upregulation plays a role in fibroblast-reduced gefitinib sensitivity in the NSCLC cell line HCC827
por: CHEN, JIA, et al.
Publicado: (2015)

Plasma Metabolomic Profiles in Recovered COVID-19 Patients without Previous Underlying Diseases 3 Months After Discharge
por: Zhang, Shujing, et al.
Publicado: (2021)

Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin
por: Hu, Yong, et al.
Publicado: (2017)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9sk629hafhaaagk35t78666cek